Ping An Bio Announces Non-Binding $30M Cash Investment, $60M Acquisition Plan With Future Biotechnology

Ping An Biomedical Co., Ltd (NASDAQ:PASW) (hereinafter referred to as "Ping An Bio") announced that it has entered into a non-binding memorandum (the "Investment Memorandum") with Future Biotechnology Group Co., Ltd (hereinafter referred to as "Future Biotechnology Group").

The Investment Memorandum outlines an initial investment of US$30 million to be paid in cash, as well as subsequent acquisitions with a consideration, in aggregate, of US$60 million to be settled in cash and share issuances (the "Consideration Shares"). The Consideration Shares are to be held escrow and released in accordance with performance targets over an evaluation period of 3 years from January 2026 to December 2028.